SNDX - CIK 0001395937
The table below shows Syndax Pharmaceuticals Inc's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$50.34M | -$95.16M | -$83.55M | -$39.23M | -$41.93M | -$22.59M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | $38.39M | $94.14M | -$99.40M | $19.91M | $8.18M | -$29.23M |
| Dividends paid | - | - | - | - | - |
Syndax Pharmaceuticals Inc reported operating cash flow of -$322.98M for fiscal year 2025. That is down 17.5% from -$274.90M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$35.16M (FY 2016) to -$322.98M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $7.92M | $930.00K | $2.17M | $2.47M | $557.00K | $960.00K |